Eli Lilly remains a top GARP opportunity, with Q3 results reinforcing its robust business growth and dominance in incretin ...

Recursion, Roche and Genentech unveiled the latest product of their nearly four-year artificial intelligence drug discovery collaboration. GSK ’s Blenrep was approved by the FDA for treatment of ...

The live event in Nashville, Tenn., featured 60-plus leaders, and also honored several companies with awards for supply chain excellence.

Before being discontinued, the P2X7 receptor blocker had cleared a master protocol study in chronic pain, though Eli Lilly ...

As weight loss market rival Novo Nordisk drew headlines for starting a bidding war over a potential $9bn acquisition of ...

Eli Lilly And Company ( ($LLY) ) has released its Q3 earnings. Here is a breakdown of the information Eli Lilly And Company presented to its ...

As of 10 AM Eastern Time, the S&P 500 slipped 0.2%, the Dow Jones Industrial Average was up 0.5%, and the Nasdaq Composite ...

Eli Lilly reported strong earnings and raised guidance. Read more on what could be next for this biotech giant.

The company's outlook for the rest of the year was rosier than in the previous quarter, when it announced cost-cutting plan ...

Novo Nordisk has made an unsolicited, approximately up to $9 billion bid for Metsera—more than a month after Pfizer announced its intent to buy the company for up to $7.3 billion.

Together, Mounjaro and Zepbound brought in $11.98 billion in the third quarter even with price decreases for the medicines.

The Big Pharma mainstay blew away EPS and revenue expectations when it reported Q3 financials, with management raising ...